Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2024-08-11 Regulatory Filings
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings
2024-08-11 English
Investor Presentation
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Earnings Presentation Q1 FY25' and contains detailed financial highlights, including revenue, EBITDA, PBT, PAT, margins, and EPS for the first quarter of fiscal year 2025. It also includes a company overview, business mix, geographic presence, and future outlook. The content is consistent with a detailed presentation aimed at investors, focusing on quarterly financial performance and business strategy. The document is not a brief announcement or a certification letter, but a comprehensive presentation of quarterly results. Therefore, it fits the category of an Interim / Quarterly Report (IR) as it contains substantive financial data and analysis for a period shorter than a full fiscal year.
2024-08-10 English
Outcome of Board Meeting
Regulatory Filings
2024-08-10 English
Financial Result Updates
Regulatory Filings
2024-08-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is an intimation letter dated August 5, 2024, informing stock exchanges about an upcoming earnings call scheduled for August 12, 2024, to discuss the operational and financial performance for Q1 FY 2024-25. It includes details such as the date, time, management representatives, and dial-in numbers for the call. The document does not contain any actual financial data or results but serves as a notification of the earnings call event. The document length is 2910 characters, which is relatively short and consistent with an announcement rather than a full transcript or report. Therefore, this document is best classified as a Call Transcript announcement (CT) or more precisely an announcement of an earnings call. Since it is an announcement of the earnings call and not the transcript itself, the closest fitting category is Call Transcript (CT) as it relates to the earnings call event.
2024-08-05 English
Board Meeting — SUPRIYA LIFESCIENCE LIMITED has informed the Exchange about Board Meeting to be held on 10-Aug-2024 to inter-alia consider and approve the Unaudited Financial results of the Company f…
Regulatory Filings
2024-08-03 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.